A Penn Medicine study shows height could be a causal risk factor in developing atrial fibrillation.
Taller people have an increased risk of developing atrial fibrillation (AFib), an irregular and often rapid heartbeat that can lead to stroke, heart failure and other complications, according to a new Penn Medicine study. The research, which reveals a strong link between the genetic variants associated with height and one’s risk for AFib, is among the first to demonstrate that height may be a causal—not correlated—risk factor for AFib. The findings were presented at the American Heart Association’s 2019 Scientific Sessionsin Philadelphia this month.
Researchers found that the risk for AFib climbed as one’s height increased, with every one-inch increase in height translating to about a three percent increase in risk of Afib—independent of other clinical factors—as compared to those at average height (5 feet and 7 inches).
“Our findings suggest it may be beneficial to incorporate height into risk-prediction tools for AFib,” says the study’s lead author Michael Levin,a cardiovascular medicine fellow at Penn. “While current guidelines advise against widespread screening for AFib, our findings show that a certain group of patients—specifically, very tall patients—may benefit from screening.”
OpenAI, DeepSeek, and Google vary widely in identifying hate speech
Neil Fasching and Yphtach Lelkes of the Annenberg School for Communication have found dramatic differences in how large language models classify hate speech, with especially large variations for language about certain demographic groups, raising concerns about bias and disproportionate harm.
Understanding order to disorder at the atomic scale opens possibilities for next-generation electronic devices
A Penn team has developed insight into the chemical and geometric mechanisms underlying the synthesis of new 2D materials, paving the way for next-gen devices, biomedical applications, and cleaner, quicker energy conversion and storage.
(From left) Kevin B. Mahoney, chief executive officer of the University of Pennsylvania Health System; Penn President J. Larry Jameson; Jonathan A. Epstein, dean of the Perelman School of Medicine (PSOM); and E. Michael Ostap, senior vice dean and chief scientific officer at PSOM, at the ribbon cutting at 3600 Civic Center Boulevard.
Reimagined Penn Medicine facility set to usher in a bold new era of Immune Health discovery
3600 Civic Center Boulevard will bring together key researchers and technologies in Immune Health, the Colton Center for Autoimmunity, and infectious diseases to drive breakthrough science.
